Elsevier

Vaccine

Volume 16, Issue 20, December 1998, Pages 2058-2068
Vaccine

Paper
Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use

https://doi.org/10.1016/S0264-410X(98)00080-2Get rights and content

Abstract

Two quite different adjuvants, currently under development for use in humans, have been examined for their effects on the magnitude and type of immunity elicited in response to inactivated influenza vaccine. Immunostimulating complexes (ISCOM™ adjuvant) contain the saponin ISCOPREP™ 703, and SPT is an oil-in-water emulsion of squalane, non-ionic block copolymer (L121) and Tween 80. Influenza virus vaccines formulated in either adjuvant were far superior to the non-adjuvanted aqueous vaccine in eliciting antibody and T-cell responses in mice, particularly at lower doses of antigen. In addition, the vaccines containing adjuvant were superior in eliciting protective immunity. One of the shortcomings of the unadjuvanted inactivated influenza vaccine was its inability to elicit a primary proliferative T-cell response. However, after one dose of either adjuvaned vaccine, strong proliferative responses were achieved. We also show that subcutaneous vaccination with inactivated vaccines is capable of modulating the isotype profile of antibody secreting cells generated in the lungs of mice in response to intranasal challenge with live virus. In this system, the isotype of antibody elicited after challenge of mice that had received ISCOM vaccine more closely mimicked that of animals vaccinated with live virus.

References (62)

  • K. Lovgren et al.

    Antigenic presentation of small molecules and peptides conjugated to a preformed iscom as carrier

    J. Immunol. Methods

    (1987)
  • N.E. Byars et al.

    Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity

    Vaccine

    (1987)
  • L.F. Woodard et al.

    Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants

    Vaccine

    (1985)
  • D.C. Jackson et al.

    Antigenic determinants of influenza virus hemagglutinin. XII. The epitopes of a synthetic peptide representing the C-terminus of HA1

    Virology

    (1986)
  • J.D. Sedgwick et al.

    A solid-phase immunoenzymatic technique for the enumeration of specific antibody secreting cells

    J. Immunol. Methods

    (1983)
  • D.R. Burton

    Immunoglobulin G: functional sites

    Mol. Immunol.

    (1985)
  • G. Keren et al.

    Failure of influenza vaccination in the aged

    J. Med. Virol.

    (1988)
  • J.P. Mullooly et al.

    Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization

    Ann. Intern. Med.

    (1994)
  • K.L. Nichol et al.

    The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community

    N. Engl. J. Med.

    (1994)
  • P.A. Gross et al.

    The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature

    Ann. Intern. Med.

    (1995)
  • C.W. Potter

    Inactivated influenza virus vaccine

  • E.T. Ben-Ahmeida et al.

    IgG subclass response and protection against challenge following immunization of mice with various influenza A vaccines

    J. Med. Microbiol.

    (1994)
  • F.M. Davenport et al.

    Lack of adjuvant effect of AIPO4 on purified influenza virus haemaglutinins in man

    J. Immunol.

    (1968)
  • P. Doherty et al.

    Analysing the T cell response to influenza viruses in mouse model systems

  • A.J. McMichael et al.

    Cytotoxic T-cell immunity to influenza

    N. Engl. J. Med.

    (1983)
  • K. Lovgren et al.

    The requirement of lipids for the formation of immunostimulating complexes (iscoms)

    Biotechnol. Appl. Biochem.

    (1988)
  • B. Morein et al.

    Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses

    Nature

    (1984)
  • K. Lovgren et al.

    An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration

    Clin. Exp. Immunol.

    (1990)
  • E.T. Ben-Ahmeida et al.

    The IgA and subclass IgG responses and protection in mice immunized with influenza antigens administered as ISCOMS, with FCA ALH or as infectious virus

    Arch. Virol.

    (1992)
  • P. de Vries et al.

    Measles virus fusion protein presented in an immune-stimulating complex (iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice

    J. Gen. Virol.

    (1988)
  • A.J. Morgan et al.

    Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes

    J. Gen. Virol.

    (1988)
  • Cited by (0)

    View full text